Vericel (VCEL) Stock Price, News & Analysis

Company Overview

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients. EPICEL® (cultured epidermal autograft) is approved for use in pediatric burn patients with deep partial-thickness or full-thickness burns covering at least 30% of total body surface area. Vericel manages the entire manufacturing process—from cell collection and expansion to final product release—at its state-of-the-art cell processing facilities in the United States.

The company distributes its products across the U.S. market and has established licensing and distribution partnerships to serve patients in select international regions, including Europe, Canada and Australia. Beyond its commercial portfolio, Vericel maintains a pipeline of investigational therapies targeting tendon repair and other musculoskeletal injuries. Its research and development efforts leverage proprietary cell culture platforms and delivery technologies aimed at addressing significant unmet medical needs in regenerative medicine.

Key Stats

• Today's Range: $31.00 to $32.91
• 50-Day Range: $31.31 to $41.50
• 52-Week Range: $30.26 to $63.00
• Volume: 729,448 shs
• Average Volume: 528,538 shs
• Market Capitalization: $1.65 billion
• P/E Ratio: 272.95
• Dividend Yield: N/A
• Price Target: $60.40
• Consensus Rating: Buy

Vericel Stock Analysis - MarketRank™

Vericel scored higher than 58% of companies evaluated by MarketBeat, and ranked 538th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Vericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Vericel has a consensus price target of $60.40, representing about 87.4% upside from its current price of $32.23.

Amount of Analyst Coverage

Vericel has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 214.29%

Earnings Growth

Earnings for Vericel are expected to grow by 214.29% in the coming year, from $0.14 to $0.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vericel is 268.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vericel is 268.15, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 75.77.

Price to Book Value per Share Ratio

Vericel has a P/B Ratio of 5.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.50% of the float of Vericel has been sold short.

Short Interest Ratio / Days to Cover

Vericel has a short interest ratio ("days to cover") of 9.6.

Change versus previous month

Short interest in Vericel has recently decreased by 2.31%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vericel does not currently pay a dividend.

Dividend Growth

Vericel does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.50% of the float of Vericel has been sold short.

Short Interest Ratio / Days to Cover

Vericel has a short interest ratio ("days to cover") of 9.6.

Change versus previous month

Short interest in Vericel has recently decreased by 2.31%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.93

News Sentiment

Vericel has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Vericel this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for VCEL on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vericel insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.20% of the stock of Vericel is held by insiders.

VCEL Stock Analysis - Frequently Asked Questions

How have VCEL shares performed this year?

Vericel's stock was trading at $54.91 at the beginning of the year. Since then, VCEL stock has decreased by 41.3% and is now trading at $32.2250.

How were Vericel's earnings last quarter?

Vericel Corporation (NASDAQ:VCEL) issued its quarterly earnings data on Thursday, July, 31st. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.03. The company's revenue was up 20.1% compared to the same quarter last year.
Read the conference call transcript.

Who are Vericel's major shareholders?

Top institutional shareholders of Vericel include Brown Capital Management LLC (5.57%), Conestoga Capital Advisors LLC (4.89%), State Street Corp (4.83%) and Invesco Ltd. (3.95%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Paul K Wotton, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Jonathan Siegal, Michael Halpin and Sean C Flynn.
View institutional ownership trends.

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Palo Alto Networks (PANW) and Netflix (NFLX).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VCEL
• CIK: 887359
• Web: www.vcel.com
• Phone: (617) 588-5555
• Fax: 617-588-5554
• Employees: 300
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Vericel: $60.40
• High Price Target: $67.00
• Low Price Target: $51.00
• Potential Upside/Downside: +92.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.12
• Trailing P/E Ratio: 261.86
• Forward P/E Ratio: 224.43
• P/E Growth: N/A
• Net Income: $10.36 million
• Net Margins: 2.85%
• Pretax Margin: 2.91%
• Return on Equity: 2.47%
• Return on Assets: 1.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.97
• Quick Ratio: 4.56

Sales & Book Value

• Annual Sales: $237.22 million
• Price / Sales: 6.68
• Cash Flow: $0.31 per share
• Price / Cash Flow: 102.98
• Book Value: $5.92 per share
• Price / Book: 5.31

Miscellaneous

• Outstanding Shares: 50,460,000
• Free Float: 46,827,000
• Market Cap: $1.59 billion
• Optionable: Optionable
• Beta: 1.33